Panageas KS - Search Results

1

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK. Grommes C, et al. Among authors: panageas ks. Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19. Blood. 2019. PMID: 30567753 Free PMC article. Clinical Trial.

2

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. Modi S, et al. Among authors: panageas ks. Breast Cancer Res Treat. 2005 Mar;90(2):157-63. doi: 10.1007/s10549-004-3974-0. Breast Cancer Res Treat. 2005. PMID: 15803362 Clinical Trial.

3

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. Modi S, et al. Among authors: panageas ks. Clin Breast Cancer. 2005 Apr;6(1):55-60. doi: 10.3816/CBC.2005.n.009. Clin Breast Cancer. 2005. PMID: 15899073 Clinical Trial.

4

Delayed neurotoxicity in primary central nervous system lymphoma.

Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE. Omuro AM, et al. Among authors: panageas ks. Arch Neurol. 2005 Oct;62(10):1595-600. doi: 10.1001/archneur.62.10.1595. Arch Neurol. 2005. PMID: 16216945

5

Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis.

Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE. Panageas KS, et al. Cancer. 2005 Dec 1;104(11):2466-72. doi: 10.1002/cncr.21481. Cancer. 2005. PMID: 16240449 Free article.

6

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. Hormigo A, et al. Among authors: panageas ks. Clin Cancer Res. 2006 Oct 1;12(19):5698-704. doi: 10.1158/1078-0432.CCR-06-0181. Clin Cancer Res. 2006. PMID: 17020973

7

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.

Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM. Abrey LE, et al. Among authors: panageas ks. J Clin Oncol. 2006 Dec 20;24(36):5711-5. doi: 10.1200/JCO.2006.08.2941. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116938

8

Patterns of treatment in older adults with primary central nervous system lymphoma.

Panageas KS, Elkin EB, Ben-Porat L, Deangelis LM, Abrey LE. Panageas KS, et al. Cancer. 2007 Sep 15;110(6):1338-44. doi: 10.1002/cncr.22907. Cancer. 2007. PMID: 17647247 Free article.

9

Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.

Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE. Levy O, et al. Among authors: panageas ks. Cancer. 2008 Jan 1;112(1):151-6. doi: 10.1002/cncr.23149. Cancer. 2008. PMID: 17999414 Free article.

10

Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.

Ekenel M, Iwamoto FM, Ben-Porat LS, Panageas KS, Yahalom J, DeAngelis LM, Abrey LE. Ekenel M, et al. Among authors: panageas ks. Cancer. 2008 Sep 1;113(5):1025-31. doi: 10.1002/cncr.23670. Cancer. 2008. PMID: 18618509 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

283 results

Search Page